Avadel Recognizes World Narcolepsy Day and Announces New Data Presentations from Pivotal Phase 3 REST-ON Trial of FT218 at Upcoming Conference
World Narcolepsy Day was established by 28 patient advocacy organizations across six continents to raise global awareness and improve outcomes for people with narcolepsy.
- World Narcolepsy Day was established by 28 patient advocacy organizations across six continents to raise global awareness and improve outcomes for people with narcolepsy.
- As part of Avadels support of World Narcolepsy Day, the Company recently launched Narcolepsy Disrupts , a narcolepsy awareness campaign for patients, their loved ones and healthcare providers about the importance of prioritizing more natural sleep patterns.
- World Narcolepsy Day is a much needed public awareness campaign, helping to reduce stigma and increase visibility for those living with narcolepsy around the world.
- In March 2020, Avadel completed the REST-ON study, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in adults with narcolepsy.